feed,title,long_url,short_url
Benzinga,GDS Clocks 24% Revenue Growth In Q2; Cuts FY22 Outlook,https://benzinga.com/news/earnings/22/08/28599668/gds-clocks-24-revenue-growth-in-q2-cuts-fy22-outlook,https://bit.ly/3Keaw2h
Benzinga,"This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says",https://benzinga.com/general/biotech/22/08/28599191/mizuho-sees-eye-disease-gene-therapy-significant-driver-for-this-stock-rather-covid-19-shot,https://bit.ly/3cfffUQ
